Female incompetence, misogyny and xenophobia or a faulty marital policy on the part of the late Byzantine emperors? von Melichar, Petra

Volltext

Imperial Women as Emissaries, Intermediaries, and Conciliators in the Palaiologan Era von Melichar, Petra

Volltext

GOD, SLAVE AND A NUN : A CASE FROM LATE MEDIEVAL CYPRUS von Melichar, Petra

Volltext

comptes-rendus von Ćirić, Jasmina, Skálová, Zuzana, Brzozowska, Zofia A, Husar, Jan, Mrňávek, Tomáš, Melichar, Petra, Hájková, Jitka, D-Vasilescu, Elena Ene

Volltext

Notes informatives von Gratziou, Olga, Řoutil, Michal, Čechová, Martina, Konečný, Martin, Melichar, Petra, Georgiou, Stavros G

Volltext

NOTICES BIBLIOGRAPHIQUES von Demoen, K., Yannopoulos, P., Ceulemans, R., Bentein, K., Fernández, T., Melichar, Petra, Canart, P., De Siena, A. A., Mossay, J.

Volltext

Comptes rendus von Melichar, Petra, Torres Prieto, Susana, Panagopoulos, Spyros P

Volltext

Comptes-rendus von Leonte, Florin, Kulhánková, Markéta, Melichar, Petra, Gkantzios-Drápelová, Pavla, Meško, Marek, Jančárková, Julie

Volltext

Comptes-Rendus von Roach, Andrew P, Melichar, Petra, Constantinou, Stavroula, Oltean, Daniel, Nicolini, Vincent

Volltext

Comtes Rendus von Tsoutsos, George, Leonte, Florin, Angold, Michael, Bočková Loudová, Kateřina, Kulhánková, Markéta, Feldman, Alex M, Kuttner-Hom, Stanislas, Tinterri, Danielle, Brandejs, Jan, Böhm, Marcin, Sophoulis, Panos, Melichar, Petra

Volltext

Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma von Rini, Brian I, Plimack, Elizabeth R, Stus, Viktor, Gafanov, Rustem, Hawkins, Robert, Nosov, Dmitry, Pouliot, Frédéric, Alekseev, Boris, Soulières, Denis, Melichar, Bohuslav, Vynnychenko, Ihor, Kryzhanivska, Anna, Bondarenko, Igor, Azevedo, Sergio J, Borchiellini, Delphine, Szczylik, Cezary, Markus, Maurice, McDermott, Raymond S, Bedke, Jens, Tartas, Sophie, Chang, Yen-Hwa, Tamada, Satoshi, Shou, Qiong, Perini, Rodolfo F, Chen, Mei, Atkins, Michael B, Powles, Thomas

Volltext

Lenvatinib plus Pembrolizumab or Everolimus for Advanced Renal Cell Carcinoma von Motzer, Robert, Alekseev, Boris, Rha, Sun-Young, Porta, Camillo, Eto, Masatoshi, Powles, Thomas, Grünwald, Viktor, Hutson, Thomas E, Kopyltsov, Evgeny, Méndez-Vidal, María J, Kozlov, Vadim, Alyasova, Anna, Hong, Sung-Hoo, Kapoor, Anil, Alonso Gordoa, Teresa, Merchan, Jaime R, Winquist, Eric, Maroto, Pablo, Goh, Jeffrey C, Kim, Miso, Gurney, Howard, Patel, Vijay, Peer, Avivit, Procopio, Giuseppe, Takagi, Toshio, Melichar, Bohuslav, Rolland, Frederic, De Giorgi, Ugo, Wong, Shirley, Bedke, Jens, Schmidinger, Manuela, Dutcus, Corina E, Smith, Alan D, Dutta, Lea, Mody, Kalgi, Perini, Rodolfo F, Xing, Dongyuan, Choueiri, Toni K

Volltext

Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma von Choueiri, Toni K, Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Ferguson, Thomas, Chang, Yen-Hwa, Hajek, Jaroslav, Symeonides, Stefan N, Lee, Jae Lyun, Sarwar, Naveed, Thiery-Vuillemin, Antoine, Gross-Goupil, Marine, Mahave, Mauricio, Haas, Naomi B, Sawrycki, Piotr, Gurney, Howard, Chevreau, Christine, Melichar, Bohuslav, Kopyltsov, Evgeniy, Alva, Ajjai, Burke, John M, Doshi, Gurjyot, Topart, Delphine, Oudard, Stephane, Hammers, Hans, Kitamura, Hiroshi, Bedke, Jens, Perini, Rodolfo F, Zhang, Pingye, Imai, Kentaro, Willemann-Rogerio, Jaqueline, Quinn, David I, Powles, Thomas

Volltext

Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a... von Cescon, David W, Nowecki, Zbigniew, Gallardo, Carlos, Holgado, Esther, Iwata, Hiroji, Masuda, Norikazu, Otero, Marco Torregroza, Loi, Sherene, Guo, Zifang, Gonzalo, Gomez Abuin, Diego, Kaen, Matias, Molina, Stephen, Begbie, Philip, Clingan, Sherene, Loi, Dhanusha, Sabanathan, Donatienne, Taylor, Domicio Carvalho, Lacerda, Fernando Cezar Toniazzi, Lissa, Felipe, Silva, Joanne, Yu, Alejandro, Acevedo, Bohuslav, Melichar, Katarina, Petrakova, Jana, Prausova, Erik, Jakobsen, Jeanette, Jensen, Soren, Linnet, Tamas, Lorincz, Herve, Bonnefoi, Isabelle, Desmoulins, Jens-Uwe, Blohmer, Nadia, Harbeck, Jens, Huober, Christian, Kurbacher, Sibylle, Loibl, Tibor, Csoszi, Zsuzsanna, Kahan, Karoly, Mahr, John, Crown, Seamus, O'Reilly, Takaaki, Fujii, Hiroji, Iwata, Hirofumi, Mukai, Seigo, Nakamura, Shoichiro, Ohtani, Akihiko, Osaki, Yasuaki, Sagara, Masato, Takahashi, Koichiro, Tsugawa, Junichiro, Watanabe, Yutaka, Yamamoto, Teruo, Yamauchi, Angel, Gomez Villanueva, Alejandro, Juarez Ramiro, Flavia, Morales-Vasquez, David, Porter, Ewa, Chmielowska, Ewa, Nowakowska-Zajdel, Zbigniew, Nowecki, Barbara, Radecka, Joanna, Streb, Alexander, Arkhipov, Natalia, Fadeeva, Oleg, Lipatov, Kwong Hwa, Park, Yeon Hee, Park, Begona, Bermejo de las Heras, Javier, Cortes, Luis, de la Cruz Merino, Jose, Garcia Saenz, Maria, Gion, Mei-Ching, Liu, Chiun-Sheng, Huang, Cagatay, Arslan, Irfan, Cicin, Erhan, Gokmen, Ozgur, Ozyilkan, Sinan, Yavuz, Janine, Graham, Mark, Tuthill, Christopher, Twelves, Duncan, Wheatley, Oleksii, Kolesnik, Olena, Kolesnik, Alla, Nasonova, Olga, Ponomarova, Dmytro, Trukhin, Sibel, Blau, Madhu, Chaudhry, Scott, Cole, William, Irvin, Randa, Loutfi, Janice, Lu, Coral, Omene, Timothy, Panella, Michael, Schleider, Robert, Siegel, Michael, Simon, Frances, Valdes-Albini

Volltext

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, op... von Burtness, Barbara, Greil, Richard, de Castro, Gilberto, Fuereder, Thorsten, Ngamphaiboon, Nuttapong, Wan Ishak, Wan Zamaniah, Hong, Ruey-Long, González Mendoza, René, Zhang, Yayan, Gumuscu, Burak, Boyer, Michael, Hughes, Brett, Rischin, Danny, Taylor, Anne, Burian, Martin, Barrios, Carlos Henrique, de Castro Junior, Dalvaro Oliveira, Franke, Fabio Andre, Girotto, Gustavo, Lima, Iane Pinto Figueiredo, Nicolau, Ulisses Ribaldo, Santos, Lucas, Victorino, Ana-Paula, Chua, Neil, Couture, Felix, Hansen, Aaron, Hilton, John, McCarthy, Joy, Soulieres, Denis, Ascui, Rodrigo, Villanueva, Luis, Kral, Zdenek, Prausova, Jana, Vosmik, Milan, Jurgens, Hannes, Putnik, Kadri, Gruenwald, Viktor, Boukovinas, Ioannis, Psyrri, Amanda, Kwong, Dora, Csoszi, Tibor, Horvai, Geza, Landherr, Laszlo, Szota, Judit, Billan, Salem, Nole, Franco, Fujimoto, Yasushi, Hanai, Nobuhiro, Hara, Hiroki, Shimizu, Yasushi, Sugasawa, Masashi, Takahashi, Shunji, Tanaka, Kaoru, Ueda, Tsutomu, Wan Ishak, Wan Zamaniah, Gonzalez Mendoza, Rene, Buter, Jan, Hoeben, Ann, Bratland, Aase, Querol, John, Regala, Eugenio Emmanuel, Villegas, Ellie May, Karpenko, Andrey, Zarubenkov, Oleg, Cohen, Graham, du Toit, Johanna, Jordaan, Christa, Landers, Gregory, Ruff, Paul, Tabane, Neonyana, Brana, Irene, Iglesias Docampo, Lara, Abel, Edvard, Muratidu, Valentina, Nielsen, Niels, Cristina, Valerie, Rothschild, Sacha, Yang, Muh-Hwa, Yeh, Su-Peng, Ngamphaiboon, Nuttapong, Cicin, Irfan, Ekenel, Meltem, Harrington, Kevin, Ali, Haythem, Anderson, Daniel, Bruce, Justine, Halmos, Balazs, Hegde, Upendra, Khan, Saad, Martincic, Danko, McCune, Steven, Misiukiewicz, Krzysztof, Neupane, Prakash, Nunnink, Johannes, O'Malley, Meaghan, Powell, Steven, Redman, Rebecca, Rella, Vincent, Rocha Lima, Chaio, Wong, Stuart

Volltext

Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma von Choueiri, Toni K., Tomczak, Piotr, Park, Se Hoon, Venugopal, Balaji, Ferguson, Tom, Symeonides, Stefan N., Hajek, Jaroslav, Chang, Yen-Hwa, Lee, Jae-Lyun, Sarwar, Naveed, Haas, Naomi B., Gurney, Howard, Sawrycki, Piotr, Mahave, Mauricio, Gross-Goupil, Marine, Zhang, Tian, Burke, John M., Doshi, Gurjyot, Melichar, Bohuslav, Kopyltsov, Evgeniy, Alva, Ajjai, Oudard, Stephane, Topart, Delphine, Hammers, Hans, Kitamura, Hiroshi, McDermott, David F., Silva, Adriano, Winquist, Eric, Cornell, Jerry, Elfiky, Aymen, Burgents, Joseph E., Perini, Rodolfo F., Powles, Thomas

Volltext

First-Line Selpercatinib or Chemotherapy and Pembrolizumab in RET Fusion–Positive NSCLC von Zhou, Caicun, Solomon, Benjamin, Loong, Herbert H., Park, Keunchil, Pérol, Maurice, Arriola, Edurne, Novello, Silvia, Han, Baohui, Zhou, Jianying, Ardizzoni, Andrea, Mak, M. Perez, Santini, Fernando C., Elamin, Yasir Y., Drilon, Alexander, Wolf, Jürgen, Payakachat, Nalin, Uh, Minji K., Rajakumar, Deborah, Han, Hongmei, Puri, Tarun, Soldatenkova, Victoria, Lin, A. Bence, Lin, Boris K., Goto, Koichi

Volltext

How Do Observable Characteristics of Post-Mining Forests Affect Their Attractiveness for Recreation? von Braun Kohlova, Marketa, Nepozitkova, Petra, Melichar, Jan

Volltext

Afatinib versus methotrexate as second-line treatment in patients with recurrent or metastatic squamous-cell carcinoma of the head and neck progressing on or after platinum-based t... von Machiels, Jean-Pascal H, Prof, Haddad, Robert I, MD, Fayette, Jérôme, MD, Licitra, Lisa F, MD, Tahara, Makoto, MD, Vermorken, Jan B, Prof, Clement, Paul M, Prof, Gauler, Thomas, MD, Cupissol, Didier, MD, Grau, Juan José, MD, Guigay, Joël, Prof, Caponigro, Francesco, MD, de Castro, Gilberto, PhD, de Souza Viana, Luciano, MD, Keilholz, Ulrich, Prof, del Campo, Joseph M, MD, Cong, Xiuyu Julie, PhD, Ehrnrooth, Eva, MD, Cohen, Ezra E W, MD

Volltext

Standard first-line chemotherapy with or without nintedanib for advanced ovarian cancer (AGO-OVAR 12): a randomised, double-blind, placebo-controlled phase 3 trial von du Bois, Andreas, Prof, Kristensen, Gunnar, Prof, Ray-Coquard, Isabelle, Prof, Reuss, Alexander, MSc, Pignata, Sandro, MD, Colombo, Nicoletta, Prof, Denison, Ursula, MD, Vergote, Ignace, Prof, del Campo, Jose M, MD, Ottevanger, Petronella, PhD, Heubner, Martin, MD, Minarik, Thomas, PhD, Sevin, Emmanuel, MD, de Gregorio, Nikolaus, MD, Bidziński, Mariusz, Prof, Pfisterer, Jacobus, Prof, Malander, Susanne, MD, Hilpert, Felix, Prof, Mirza, Mansoor R, MD, Scambia, Giovanni, Prof, Meier, Werner, Prof, Nicoletto, Maria O, MD, Bjørge, Line, Prof, Lortholary, Alain, MD, Sailer, Martin Oliver, PhD, Merger, Michael, MD, Harter, Philipp, MD

Volltext